Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787647 | 0.85 | KMT2A (0.47) | KMT2AHDAC6ROCK2ROCK1TP53 | |
| SCHEMBL1792607 | 0.84 | ROCK2 (0.48) | KMT2AROCK2CYP3A4 | |
| SCHEMBL1787944 | 0.84 | MAPT (0.41) | KMT2AHDAC6ROCK2TP53OPRM1 | |
| SCHEMBL1786312 | 0.83 | RAB9A (0.42) | KMT2AHDAC6ROCK2ROCK1OPRM1 | |
| SCHEMBL1789788 | 0.83 | ABCB1 (0.39) | KMT2AHDAC6ROCK2ROCK1MAPT | |
| SCHEMBL1791556 | 0.82 | ITK (0.44) | KMT2AHDAC6ROCK2ROCK1 | |
| SCHEMBL1788606 | 0.82 | NAMPT (0.48) | KMT2AHDAC6ROCK2MAPTCYP3A4 | |
| SCHEMBL1787644 | 0.82 | ALDH1A1 (0.53) | KMT2ATP53MAPT | |
| SCHEMBL1789970 | 0.82 | ROCK2 (0.49) | KMT2AHDAC6ROCK2TP53MAPT | |
| SCHEMBL1787686 | 0.81 | NAMPT (0.49) | KMT2AHDAC6ROCK2ROCK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | KMT2A 731/4885HDAC6 683/4885ROCK2 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.